her asthma suddenly hits and she reaches for her inhaler
Cimzia

Content prepared by Direct Doctor Supply’s Editorial team.


Last Updated On October 15, 2026

Cimzia Side Effects – Common and Serious Reactions to Watch For

Feb 17, 2025

Chronic inflammatory conditions contribute significantly to global health burdens. According to the Centers for Disease Control and Prevention (CDC), non-communicable diseases (NCDs), such as heart disease, cancer, chronic respiratory diseases, and diabetes, are responsible for 7 out of 10 deaths in the United States.

Cimzia (certolizumab pegol) is a tumor necrosis factor (TNF) blocker commonly prescribed to adults with active Crohn’s disease and other inflammatory conditions. While it effectively reduces inflammation and improves patients’ quality of life, it is essential to be aware of its potential side effects. Understanding both the common and severe reactions can help patients and healthcare providers make informed treatment decisions.

This article explores the Cimzia side effects, detailing the most frequently reported reactions as well as serious complications that require immediate medical attention.

Key Takeaways

  • Cimzia is effective for treating autoimmune conditions, but some patients may experience side effects during treatment.
  • Common side effects include injection site reactions, fatigue, mild infections, and gastrointestinal discomfort.
  • Severe reactions may involve serious infections, increased cancer risk, neurological complications, and autoimmune responses that require immediate medical attention.
  • Patient screening, regular health monitoring, and education on potential symptoms are crucial for effectively managing side effects.
Consult our sales team

If you’re interested in this product.

Book a Meeting

About: Trusted by over 2,000+ global clients since 2014, Direct Doctor Supply has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Direct Doctor Supply offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world.

Common Side Effects of Cimzia

While Cimzia is effective for treating various autoimmune disorders, some patients may experience common side effects. These can often be managed with appropriate care and attention.

pain in the finger
  • Injection Site Reactions (Redness, Swelling, Pain): Injection site reactions are among the most frequently reported Cimzia side effects. Some patients may also develop a rash from using Cimzia, which typically resolves within a few days. 
  • Fatigue and General Malaise as Commonly Reported Patient Experiences: Many patients report fatigue and malaise while taking Cimzia, leading to low energy levels and difficulty performing daily activities. If these symptoms persist or significantly impact your quality of life, speak with your healthcare provider about possible treatment adjustments or lifestyle modifications to help manage fatigue.
  • Increased Risk of Upper Respiratory Infections and Mild Viral Illnesses: Cimzia may increase the risk of upper respiratory infections and mild viral illnesses, such as sore throat, cough, and nasal congestion.
  • Gastrointestinal Discomfort, Including Nausea or Diarrhea: Some individuals experience gastrointestinal discomfort while using Cimzia, including nausea, diarrhea, or abdominal pain. If gastrointestinal issues persist or worsen, consult your healthcare provider.

While Cimzia helps manage systemic inflammation associated with autoimmune conditions such as rheumatoid and psoriatic arthritis, practitioners exploring options for localized knee osteoarthritis pain may also consider Orthovisc. Direct Doctor Supply is a trusted online distributor that offers authentic products for clinics, healthcare professionals, and consumers looking to buy Orthovisc wholesale. Orthovisc is intended for knee osteoarthritis and joint inflammation but is not a substitute for Cimzia in treating autoimmune conditions.

Serious and Rare Side Effects of Cimzia

Despite effectively treating autoimmune conditions, Cimzia may lead to serious and rare side effects. Awareness of these potential reactions is crucial for timely intervention and optimal health management.

painful stomach
  • Infections: Cimzia can increase the risk of serious infections, including tuberculosis, bacterial, fungal, and viral infections. Symptoms may include fever, chills, muscle aches, and cough.
  • Cancer: There is an increased risk of certain cancers, such as lymphoma and skin cancer, associated with Cimzia use. Regular monitoring is essential.
  • Heart Failure: Cimzia may worsen heart failure in some patients. Symptoms include swelling of ankles or feet, shortness of breath, and weight gain.
  • Neurological Disorders: Rarely, Cimzia can cause neurological issues like multiple sclerosis, presenting with dizziness, numbness, or vision changes.
  • Liver Enzyme Elevation: Elevated liver enzymes can indicate potential liver inflammation. Regular blood tests are recommended to monitor liver function.

If you experience any of these symptoms, contact your healthcare provider promptly. Regular check-ups and open communication with your doctor are vital for safe, effective treatment with Cimzia.

Clinical Strategies for Managing Cimzia Side Effects

Managing Cimzia (certolizumab pegol) side effects requires proactive clinical strategies to protect patient safety and well-being.

  • Pre-Treatment Screening: Before starting Cimzia, screen patients for tuberculosis (TB) and other infections. A negative TB test is generally required, but additional screening may be necessary for those with a history of infections or compromised immunity.
  • Regular Monitoring: Ongoing blood work monitoring is essential. A complete blood count (CBC) helps detect changes in blood cells that may indicate issues like infection or anemia. Liver enzyme tests also help ensure the medication isn’t causing liver damage.
  • Dose Adjustments: Healthcare providers may recommend dose adjustments or discontinuing Cimzia for patients at higher risk of severe side effects. Individuals with a history of malignancy, autoimmune disorders, or infections may need more frequent monitoring or dosage adjustments. 

Educating patients to recognize and report severe symptoms is essential for effective healthcare management. When well-informed, patients can promptly identify warning signs, leading to early detection and treatment of potential health issues. 

Long-Term Cimzia Safety Findings From the SECURE Registry

A 2025 study published in Crohn’s & Colitis 360, titled Certolizumab Pegol Treatment in Patients With Crohn’s Disease: Final Safety Data From the SECURE Registry, evaluated long-term safety outcomes in 3,072 adults with Crohn’s disease monitored for up to 8 years. The researchers found that overall malignancy rates were similar between certolizumab pegol and comparator treatment groups.

However, patients with any certolizumab pegol exposure had higher observed rates of serious infections and hypersensitivity or anaphylactic reactions compared with the comparator group. Concomitant thiopurine use was also associated with higher odds of non-melanoma skin cancer. Although no new safety signals were identified, these findings highlight the importance of individualized risk assessment, infection monitoring, and reviewing concomitant immunosuppressive therapies when managing Cimzia treatment.[5]

Conclusion

Cimzia (certolizumab pegol) is a highly effective treatment for autoimmune disorders and offers significant relief for many patients. However, like all medications, Cimzia side effects may occur; some are mild and manageable, while others may require immediate medical attention. Skin reactions, including a Cimzia rash, are among the side effects patients should watch for.

Knowing these possible reactions and staying in close communication with your healthcare provider are key to using Cimzia safely and effectively. Regular monitoring, proactive symptom management, and early intervention can help minimize risks and improve treatment outcomes. If you experience any concerning symptoms, seek medical advice promptly to continue benefiting from Cimzia while safeguarding your health.

FAQs

1. What is Cimzia?

Cimzia (certolizumab pegol) is a prescription medication that blocks Tumor Necrosis Factor (TNF). It treats various autoimmune conditions by suppressing the immune system to reduce inflammation.

2. What conditions does Cimzia treat?

Cimzia is approved for treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, Crohn’s disease, and plaque psoriasis.

3. How is Cimzia administered?

Cimzia is administered via subcutaneous injection. The dosing schedule varies depending on the condition being treated. 

4. Can Cimzia be used during pregnancy or breastfeeding?

The use of Cimzia during pregnancy or breastfeeding should be discussed with your healthcare provider, as it may not be recommended.

Need help, additional info, or customized deals?

Talk with our sales representative.

Book a Meeting

Citations

[1] Autoimmune Disorders: MedlinePlus Medical Encyclopedia. MedlinePlus, 2023. https://medlineplus.gov/ency/article/000816.htm. Accessed 21 Sept. 2026.

[2] Hacker, K. “The Burden of Chronic Disease.” Mayo Clinic Proceedings Innovations Quality & Outcomes, vol. 8, no. 1, 2024, pp. 112–19. doi:10.1016/j.mayocpiqo.2023.08.005.

[3] Cimzia: Side Effects, Dosage & Uses. Drugs.com. https://www.drugs.com/cimzia.html.

[4] Medication Guide Cimzia® (CIM-Zee-Uh) (Certolizumab Pegol) Lyophilized Powder or Solution for Subcutaneous Use. UCB. Accessed 17 Feb. 2025.

[5] Lichtenstein, Gary R., et al. “Certolizumab Pegol Treatment in Patients With Crohn’s Disease: Final Safety Data From the SECURE Registry.” Crohn’s & Colitis 360, vol. 7, no. 1, 25 Jan. 2025, p. otae083. doi:10.1093/crocol/otae083. PubMed Central. Accessed 21 Sept. 2026.

Sourcing and accuracy for this article follow our Editorial policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published